Veloxis Pharmaceuticals, Inc. v. Alkem Laboratories Ltd.

Case Overview & Background

This patent infringement case represents a standard Hatch-Waxman dispute between a brand-name pharmaceutical company and a generic drug manufacturer. The plaintiff, Veloxis Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on developing and commercializing medicines for transplant patients. Its key product is Envarsus XR (tacrolimus extended-release tablets), an immunosuppressant drug used to prevent organ rejection in kidney transplant patients. The defendant, Alkem Laboratories Ltd., is a large India-based pharmaceutical company that develops and markets generic drugs globally. The litigation was initiated under the framework of the Hatch-Waxman Act, which allows generic drugmakers to challenge patents before marketing their products and gives brand-name manufacturers the right to sue for infringement, triggering an automatic 30-month stay of FDA approval for the generic version.

The dispute centered on Alkem's Abbreviated New Drug Application (ANDA No. 219575) seeking FDA approval to market a generic version of Envarsus XR prior to the expiration of Veloxis's patent protection. This filing constituted a technical act of infringement, prompting Veloxis to sue Alkem to defend its market exclusivity. The single patent asserted in the case was U.S. Patent No. 12,083,103, titled "Tacrolimus for improved treatment of transplant patients," which covers specific formulations and methods for administering the drug to improve patient outcomes.

The case was filed in the U.S. District Court for the District of Delaware, a premier and highly popular venue for patent litigation due to its judges' deep expertise in complex patent law and well-developed body of case law. The matter was assigned to Judge Maryellen Noreika, a former patent litigator with significant experience in pharmaceutical cases. This case is notable as a routine but crucial "bet-the-company" type of litigation for a specialty pharmaceutical firm like Veloxis, whose commercial success is heavily tied to the patent protection of its flagship product. The ultimate resolution via a consent judgment, which blocked Alkem's generic entry until patent expiry, underscores the strength of the asserted patent and the effectiveness of the Hatch-Waxman framework in resolving such disputes, often after a key court ruling like claim construction clarifies the scope of the patent claims.

Legal Developments and Outcome

This Hatch-Waxman litigation proceeded through several key phases before reaching a final resolution that terminated the case prior to trial. The timeline below outlines the significant legal developments in chronological order.

Filing and Initial Pleadings (2024)

• 2024-07-03: Plaintiff Veloxis Pharmaceuticals, Inc. filed a patent infringement complaint against Alkem Laboratories Ltd. The suit was triggered by Alkem's submission of an Abbreviated New Drug Application (ANDA) to the FDA, which sought approval to market a generic version of Veloxis's Envarsus XR (tacrolimus) product. The filing of the ANDA with a Paragraph IV certification constituted a technical act of infringement under 35 U.S.C. § 271(e)(2).
• Initial Filings: Following the complaint, Veloxis filed supplemental information required for ANDA cases, noting that it had received Alkem's notice letter on May 24, 2024. This filing established a 30-month stay of FDA approval for Alkem's generic, with a deadline of November 24, 2026.
• Answer and Counterclaims: Alkem responded to the complaint by filing an answer, denying infringement, and asserting counterclaims. A key component of Alkem's defense was the allegation that the asserted patent, U.S. Patent No. 12,083,103, was invalid and therefore unenforceable.

Pre-Trial and Discovery Phase (2025)

The case then entered the pre-trial phase, governed by a scheduling order issued by Judge Maryellen Noreika. This period was marked by discovery and preparations for claim construction.

• Claim Construction (Markman Hearing): A significant milestone in the litigation was the Markman hearing, held on October 20, 2025. During this hearing, both parties presented arguments to Judge Noreika regarding the proper interpretation of disputed claim terms in the '103 patent. The court's subsequent ruling on claim construction would be crucial in defining the scope of the patent's claims and would likely influence the parties' settlement positions.
• Scheduling and Discovery: Throughout late 2025, the parties engaged in discovery and jointly stipulated to several extensions of deadlines for expert reports and other pre-trial obligations, which the court granted. For example, on October 28, 2025, the court extended deadlines for expert reports into early 2026.

Parallel PTAB Proceedings

A search of the USPTO's Patent Trial and Appeal Board (PTAB) database reveals no records of any inter partes review (IPR) or post-grant review (PGR) proceedings filed by Alkem Laboratories against U.S. Patent No. 12,083,103. The absence of a parallel PTAB challenge meant the litigation remained solely focused on the district court track without the potential for a stay pending a PTAB final written decision.

Final Disposition (2026)

• 2026-01-13: Before the completion of expert discovery and well ahead of any potential trial, the parties jointly submitted, and Judge Noreika signed, a Consent Judgment. This final order terminated the case.
• Outcome: The Consent Judgment permanently enjoined Alkem Laboratories from making, using, selling, or importing its generic tacrolimus product ("Alkem ANDA Product") until the expiration of the asserted patent and several other related patents. The judgment also dismissed all of Alkem's counterclaims and affirmative defenses with prejudice. In effect, the resolution represented a victory for Veloxis, as it prevents Alkem's generic competitor from entering the market for the full life of the patents-in-suit. The civil case was officially terminated on the same day the judgment was entered.

Plaintiff's Counsel of Record

The plaintiff, Veloxis Pharmaceuticals, Inc., was represented by attorneys from the intellectual property specialty firm Fish & Richardson P.C. and the Delaware firm Farnan LLP.

Based on court filings, including the complaint and the final consent judgment, the following attorneys appeared on behalf of Veloxis:

• Name: W. Chad Shear

  • Role: Lead Counsel
  • Firm: Fish & Richardson P.C., Wilmington, DE.
  • Note on Experience: Shear is a principal at his firm and serves as the managing principal of the Delaware office; he has extensive experience leading Hatch-Waxman and other life sciences patent litigation.

• Name: Brian E. Farnan

  • Role: Lead Delaware Counsel
  • Firm: Farnan LLP, Wilmington, DE.
  • Note on Experience: Farnan is a founding partner of his firm and a prominent Delaware trial lawyer, having previously served as the U.S. Attorney for the District of Delaware.

• Name: Michael J. Farnan

  • Role: Delaware Counsel
  • Firm: Farnan LLP, Wilmington, DE.
  • Note on Experience: A partner at his firm, Michael Farnan focuses on intellectual property and corporate litigation and clerked for a judge on the U.S. Court of Appeals for the Third Circuit.

• Name: Jonathan E. Singer

  • Role: Of Counsel
  • Firm: Fish & Richardson P.C., New York, NY.
  • Note on Experience: Singer is a principal and the post-grant practice group leader at his firm, specializing in patent litigation and post-grant proceedings, particularly for pharmaceutical and life sciences clients.

• Name: Corrin N. Drakulich

  • Role: Of Counsel
  • Firm: Fish & Richardson P.C., Southern California (San Diego).
  • Note on Experience: As a principal, her practice concentrates on pharmaceutical patent litigation, including numerous Hatch-Waxman cases.

• Name: Esha R. Bidiwala

  • Role: Of Counsel
  • Firm: Fish & Richardson P.C., Washington, D.C.
  • Note on Experience: Bidiwala is an associate whose practice focuses on patent litigation, with experience in pharmaceuticals and biotechnology sectors.

Defendant's Counsel of Record

Based on court filings, defendant Alkem Laboratories Ltd. was represented by attorneys from the Delaware intellectual property firm Stamoulis & Weinblatt LLC. This firm regularly represents generic pharmaceutical companies in Hatch-Waxman (ANDA) litigation.

The following attorneys appeared on behalf of Alkem:

• Name: Stamatios Stamoulis

  • Role: Lead Counsel
  • Firm: Stamoulis & Weinblatt LLC, Wilmington, DE.
  • Note on Experience: A founding partner of his firm, he has over two decades of experience in patent litigation, including prior work at Fish & Richardson, P.C., and is frequently recognized as a leading IP litigator in Delaware.

• Name: Richard C. Weinblatt

  • Role: Delaware Counsel
  • Firm: Stamoulis & Weinblatt LLC, Wilmington, DE.
  • Note on Experience: A founding partner of the firm, his practice focuses on patent litigation and appeals to the Federal Circuit, and he previously practiced at Fish & Richardson, P.C.